TenX Keane Acquisition (TENKU) News

Form 8-K - Current report

Form 8-K - Current report

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

TenX Keane Acquisition Announces Contribution to Trust Account in Connection with Extension Amendment Proposal

New York, NY, Jan. 10, 2024 (GLOBE NEWSWIRE) -- TenX Keane Acquisition (Nasdaq: TENKU, TENK, TENKR) (the...

Form DEF 14A - Other definitive proxy statements

Form PRE 14A - Other preliminary proxy statements

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 425 - Prospectuses and communications, business combinations

Form 8-K - Current report

Citius Pharmaceuticals Executes Definitive Agreement to Merge Wholly Owned Subsidiary with TenX Keane Acquisition to Form Publicly Listed Citius Oncology, Inc.

Citius Pharmaceuticals Executes Definitive Agreement to Merge Wholly Owned Subsidiary with TenX Keane...

Form 8-K - Current report

TenX Keane Acquisition Announces Extension of the Deadline for an Initial Business Combination

New York, NY, Oct. 18, 2023 (GLOBE NEWSWIRE) -- TenX Keane Acquisition (the “Company”) (NASDAQ: TENKU) today...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report